Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: revolving (5), turning (281), rotary (2)

Azacitidine(SC)-Venetoclax

Description: Chemotherapy Protocol Acute Myeloid Leukaemia AZACITIDINE (SC) - VENETOCLAX Regimen  AML – Azacitidine (SC) - Venetoclax Indication  Newly diagnosed acute myeloid leukaemia (AML).  Patient
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/AzacitidineSC-Venetoclax.pdf

Cytarabine(SC)-Venetoclax

Description: Chemotherapy Protocol Acute Myeloid Leukaemia CYTARABINE (SC) - VENETOCLAX Regimen  AML – Cytarabine (SC) -Venetoclax Indication  Newly diagnosed acute myeloid leukaemia (AML).  Patient
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/CytarabineSC-Venetoclax.pdf

Daratumumab SC Ver1

Description: Chemotherapy Protocol Myeloma Daratumumab Subcutaneous Regimen • Myeloma – Daratumumab (SC) Indication • Daratumumab monotherapy is recommended as an option for treating relapsed and
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab-SC-Ver1.pdf

Percutaneous endoscopic gastrostomy (PEG) tube insertion aftercare advice - patient information

Description: This factsheet explains what to expect after a percutaneous endoscopic gastrostomy (PEG) tube insertion and how to look after your PEG
Url: /Media/UHS-website-2019/Patientinformation/Endoscopy/Percutaneous-endoscopic-gastrostomy-PEG-tube-insertion-aftercare-advice-3645-PIL.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description: Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone Indication • Daratumumab in combination with lenalidomide and dexamethasone
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly cycles 1-8) Bortezomib-Daratumumab-Dexamethasone Regimen • Myeloma – DVd SC (weekly cycles 1-8) bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles1-8-Bortezomib-Daratumumab-Dexamethasone-Ver1.pdf

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description: Details of the Chemotherapy Protocol for Myeloma.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

Azacitidine5

Description: Chemotherapy Protocol Myelodysplastic Syndrome (MDS) Acute Myeloid Leukaemia (AML) Chronic Myelomonocytic Leukaemia (CMML) Azacitidine SC (5 days) This is an unlicensed
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Azacitidine5.pdf

Azacitidine5+2Ver1

Description: Chemotherapy Protocol Myelodysplastic Syndrome (MDS) Acute Myeloid Leukaemia (AML) Chronic Myelomonocytic Leukaemia (CMML) Azacitidine SC (5+2 days) This is not
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Azacitidine5-2Ver1.pdf

Guidelines only guide us

Description: Mr Wheeler considers the role of medical guidelines.
Url: /HealthProfessionals/Clinical-law-updates/Guidelines-only-guide-us.aspx

1 to 10 of 36

Previous 1 2 3 4 Next